MENU
Aim higher

APO010-in-selected-MM

A FAS ligand hexameric (APO010) and companion diagnostics in the immunotherapy of multiple myeloma

Start date: 
01-03-2016
Project Duration: 
35months
Technological Area: 
In vitro Testing, Trials
Market Area: 
Other therapeutic (including defibrillators)